Selected research
Industry Research
Oncology (Anti-cancer Drugs) Industry Research Report 2026
Market perspective
The global Oncology (Anti-cancer Drugs) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Oncology (Anti-cancer Drugs) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Oncology (Anti-cancer Drugs) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Oncology (Anti-cancer Drugs) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Oncology (Anti-cancer Drugs) include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Eli lilly, Pfizer, GlaxoSmithKline and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Oncology (Anti-cancer Drugs) market in terms of revenue (US$ million) and, where applicable, sales volume (k tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Oncology (Anti-cancer Drugs) Market by Company
Sanofi
Johnson & Johnson
Novartis
Merck
Roche
Eli lilly
Pfizer
GlaxoSmithKline
Amgen
Celgene
Oncology (Anti-cancer Drugs) Segment by Type
Blood Cancer
Gastrointestinal Cancer
Breast Cancer
Prostate Cancer
Others
Oncology (Anti-cancer Drugs) Segment by Application
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Chemotherapy
Targeted Therapy
Others
Oncology (Anti-cancer Drugs) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology (Anti-cancer Drugs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncology (Anti-cancer Drugs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology (Anti-cancer Drugs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Oncology (Anti-cancer Drugs) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Oncology (Anti-cancer Drugs) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Oncology (Anti-cancer Drugs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Blood Cancer
- Gastrointestinal Cancer
- Breast Cancer
- Prostate Cancer
- Others
Applications
- Immunotherapy (Biologic Therapy)
- Hormonal Therapy
- Chemotherapy
- Targeted Therapy
- Others
Companies covered
- Sanofi
- Johnson & Johnson
- Novartis
- Merck
- Roche
- Eli lilly
- Pfizer
- GlaxoSmithKline
- Amgen
- Celgene
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Oncology (Anti-cancer Drugs) Market Size (2021-2032)
- 2.2.2 Global Oncology (Anti-cancer Drugs) Sales (2021-2032)
- 2.2.3 Global Oncology (Anti-cancer Drugs) Market Average Price (2021-2032)
- 2.3 Oncology (Anti-cancer Drugs) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Blood Cancer
- 2.3.3 Gastrointestinal Cancer
- 2.3.4 Breast Cancer
- 2.3.5 Prostate Cancer
- 2.3.6 Others
- 2.4 Oncology (Anti-cancer Drugs) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Immunotherapy (Biologic Therapy)
- 2.4.3 Hormonal Therapy
- 2.4.4 Chemotherapy
- 2.4.5 Targeted Therapy
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Oncology (Anti-cancer Drugs) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Oncology (Anti-cancer Drugs) Sales (k tons) of Manufacturers (2021-2026)
- 3.3 Global Oncology (Anti-cancer Drugs) Revenue of Manufacturers (2021-2026)
- 3.4 Global Oncology (Anti-cancer Drugs) Average Price by Manufacturers (2021-2026)
- 3.5 Global Oncology (Anti-cancer Drugs) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Oncology (Anti-cancer Drugs), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Oncology (Anti-cancer Drugs), Product Type & Application
- 3.8 Global Manufacturers of Oncology (Anti-cancer Drugs), Established Date
- 3.9 Global Oncology (Anti-cancer Drugs) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Oncology (Anti-cancer Drugs) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Oncology (Anti-cancer Drugs) Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 Johnson & Johnson
- 4.2.1 Johnson & Johnson Company Information
- 4.2.2 Johnson & Johnson Business Overview
- 4.2.3 Johnson & Johnson Oncology (Anti-cancer Drugs) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson & Johnson Oncology (Anti-cancer Drugs) Product Portfolio
- 4.2.5 Johnson & Johnson Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Oncology (Anti-cancer Drugs) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis Oncology (Anti-cancer Drugs) Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Merck
- 4.4.1 Merck Company Information
- 4.4.2 Merck Business Overview
- 4.4.3 Merck Oncology (Anti-cancer Drugs) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Merck Oncology (Anti-cancer Drugs) Product Portfolio
- 4.4.5 Merck Recent Developments
- 4.5 Roche
- 4.5.1 Roche Company Information
- 4.5.2 Roche Business Overview
- 4.5.3 Roche Oncology (Anti-cancer Drugs) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Roche Oncology (Anti-cancer Drugs) Product Portfolio
- 4.5.5 Roche Recent Developments
- 4.6 Eli lilly
- 4.6.1 Eli lilly Company Information
- 4.6.2 Eli lilly Business Overview
- 4.6.3 Eli lilly Oncology (Anti-cancer Drugs) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Eli lilly Oncology (Anti-cancer Drugs) Product Portfolio
- 4.6.5 Eli lilly Recent Developments
- 4.7 Pfizer
- 4.7.1 Pfizer Company Information
- 4.7.2 Pfizer Business Overview
- 4.7.3 Pfizer Oncology (Anti-cancer Drugs) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pfizer Oncology (Anti-cancer Drugs) Product Portfolio
- 4.7.5 Pfizer Recent Developments
- 4.8 GlaxoSmithKline
- 4.8.1 GlaxoSmithKline Company Information
- 4.8.2 GlaxoSmithKline Business Overview
- 4.8.3 GlaxoSmithKline Oncology (Anti-cancer Drugs) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 GlaxoSmithKline Oncology (Anti-cancer Drugs) Product Portfolio
- 4.8.5 GlaxoSmithKline Recent Developments
- 4.9 Amgen
- 4.9.1 Amgen Company Information
- 4.9.2 Amgen Business Overview
- 4.9.3 Amgen Oncology (Anti-cancer Drugs) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Amgen Oncology (Anti-cancer Drugs) Product Portfolio
- 4.9.5 Amgen Recent Developments
- 4.10 Celgene
- 4.10.1 Celgene Company Information
- 4.10.2 Celgene Business Overview
- 4.10.3 Celgene Oncology (Anti-cancer Drugs) Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Celgene Oncology (Anti-cancer Drugs) Product Portfolio
- 4.10.5 Celgene Recent Developments
5 Global Oncology (Anti-cancer Drugs) Market Scenario by Region
- 5.1 Global Oncology (Anti-cancer Drugs) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Oncology (Anti-cancer Drugs) Sales by Region: 2021-2032
- 5.2.1 Global Oncology (Anti-cancer Drugs) Sales by Region: 2021-2026
- 5.2.2 Global Oncology (Anti-cancer Drugs) Sales by Region: 2027-2032
- 5.3 Global Oncology (Anti-cancer Drugs) Revenue by Region: 2021-2032
- 5.3.1 Global Oncology (Anti-cancer Drugs) Revenue by Region: 2021-2026
- 5.3.2 Global Oncology (Anti-cancer Drugs) Revenue by Region: 2027-2032
- 5.4 North America Oncology (Anti-cancer Drugs) Market Facts & Figures by Country
- 5.4.1 North America Oncology (Anti-cancer Drugs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Oncology (Anti-cancer Drugs) Sales by Country (2021-2032)
- 5.4.3 North America Oncology (Anti-cancer Drugs) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Oncology (Anti-cancer Drugs) Market Facts & Figures by Country
- 5.5.1 Europe Oncology (Anti-cancer Drugs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Oncology (Anti-cancer Drugs) Sales by Country (2021-2032)
- 5.5.3 Europe Oncology (Anti-cancer Drugs) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Oncology (Anti-cancer Drugs) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Oncology (Anti-cancer Drugs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Oncology (Anti-cancer Drugs) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Oncology (Anti-cancer Drugs) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Oncology (Anti-cancer Drugs) Market Facts & Figures by Country
- 5.7.1 South America Oncology (Anti-cancer Drugs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Oncology (Anti-cancer Drugs) Sales by Country (2021-2032)
- 5.7.3 South America Oncology (Anti-cancer Drugs) Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Oncology (Anti-cancer Drugs) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Oncology (Anti-cancer Drugs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Oncology (Anti-cancer Drugs) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Oncology (Anti-cancer Drugs) Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Oncology (Anti-cancer Drugs) Sales by Type (2021-2032)
- 6.1.1 Global Oncology (Anti-cancer Drugs) Sales by Type (2021-2032) & (k tons)
- 6.1.2 Global Oncology (Anti-cancer Drugs) Sales Market Share by Type (2021-2032)
- 6.2 Global Oncology (Anti-cancer Drugs) Revenue by Type (2021-2032)
- 6.2.1 Global Oncology (Anti-cancer Drugs) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Oncology (Anti-cancer Drugs) Revenue Market Share by Type (2021-2032)
- 6.3 Global Oncology (Anti-cancer Drugs) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Oncology (Anti-cancer Drugs) Sales by Application (2021-2032)
- 7.1.1 Global Oncology (Anti-cancer Drugs) Sales by Application (2021-2032) & (k tons)
- 7.1.2 Global Oncology (Anti-cancer Drugs) Sales Market Share by Application (2021-2032)
- 7.2 Global Oncology (Anti-cancer Drugs) Revenue by Application (2021-2032)
- 7.2.1 Global Oncology (Anti-cancer Drugs) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Oncology (Anti-cancer Drugs) Revenue Market Share by Application (2021-2032)
- 7.3 Global Oncology (Anti-cancer Drugs) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Oncology (Anti-cancer Drugs) Value Chain Analysis
- 8.1.1 Oncology (Anti-cancer Drugs) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Oncology (Anti-cancer Drugs) Production Mode & Process
- 8.2 Oncology (Anti-cancer Drugs) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Oncology (Anti-cancer Drugs) Distributors
- 8.2.3 Oncology (Anti-cancer Drugs) Customers
9 Global Oncology (Anti-cancer Drugs) Analyzing Market Dynamics
- 9.1 Oncology (Anti-cancer Drugs) Industry Trends
- 9.2 Oncology (Anti-cancer Drugs) Industry Drivers
- 9.3 Oncology (Anti-cancer Drugs) Industry Opportunities and Challenges
- 9.4 Oncology (Anti-cancer Drugs) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst